JP2009510134A5 - - Google Patents

Download PDF

Info

Publication number
JP2009510134A5
JP2009510134A5 JP2008533837A JP2008533837A JP2009510134A5 JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5 JP 2008533837 A JP2008533837 A JP 2008533837A JP 2008533837 A JP2008533837 A JP 2008533837A JP 2009510134 A5 JP2009510134 A5 JP 2009510134A5
Authority
JP
Japan
Prior art keywords
gastrin
pharmaceutical composition
seq
composition according
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2008533837A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009510134A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2006/001644 external-priority patent/WO2007041833A1/en
Publication of JP2009510134A publication Critical patent/JP2009510134A/ja
Publication of JP2009510134A5 publication Critical patent/JP2009510134A5/ja
Withdrawn legal-status Critical Current

Links

JP2008533837A 2005-10-07 2006-10-06 Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用 Withdrawn JP2009510134A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US72491905P 2005-10-07 2005-10-07
PCT/CA2006/001644 WO2007041833A1 (en) 2005-10-07 2006-10-06 Combined use of dpp iv inhibitors and gastrin compounds

Publications (2)

Publication Number Publication Date
JP2009510134A JP2009510134A (ja) 2009-03-12
JP2009510134A5 true JP2009510134A5 (https=) 2009-09-24

Family

ID=37942251

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008533837A Withdrawn JP2009510134A (ja) 2005-10-07 2006-10-06 Ｄｐｐ−ｉｖ阻害剤およびガストリン化合物の組み合わせ使用

Country Status (8)

Country Link
US (2) US20100144613A1 (https=)
EP (1) EP1951286A4 (https=)
JP (1) JP2009510134A (https=)
CN (1) CN101365476A (https=)
AU (1) AU2006301892A1 (https=)
BR (1) BRPI0616949A2 (https=)
CA (1) CA2625150A1 (https=)
WO (1) WO2007041833A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL156828A0 (en) 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
EP1837031B1 (en) 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
US7560425B2 (en) 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
US20110020797A1 (en) * 2007-02-09 2011-01-27 Bristol-Myers Squibb Company Methods For Identifying Patients With An Increased Likelihood Of Responding To DPP-IV Inhibitors
RU2010114025A (ru) * 2007-09-11 2011-10-20 Мондобайотек Лабораториз Аг (Li) ПРИМЕНЕНИЕ ПЕПТИДА Gly-Arg-Gly-Asp-Asn-Pro В КАЧЕСТВЕ ТЕРАПЕВТИЧЕСКОГО СРЕДСТВА
EP2190533A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
WO2010079433A2 (en) * 2009-01-07 2010-07-15 Glenmark Pharmaceuticals, S.A. Pharmaceutical composition that includes a dipeptidyl peptidase-iv inhibitor
US8808689B1 (en) * 2012-09-27 2014-08-19 Perle Bioscience, Inc. Insulin independence among patients with diabetes utilizing a PPI in combination with an immune tolerance agent
HRP20250272T1 (hr) 2017-10-19 2025-04-25 Teijin Pharma Limited Derivati benzimidazola i njihova uporaba
US12077524B2 (en) * 2018-12-28 2024-09-03 Mitsubishi Tanabe Pharma Corporation Crystal of pyrrolidine compound
US20240269194A1 (en) * 2021-06-10 2024-08-15 City Of Hope Compositions and methods for islet cell transplants

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6558952B1 (en) * 1992-12-14 2003-05-06 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US5885956A (en) * 1992-12-14 1999-03-23 Research Triangle Pharmaceuticals Treatment for diabetes using a gastrin/CCK receptor ligand and an EGF receptor ligand
GB9409496D0 (en) * 1994-05-12 1994-06-29 London Health Ass Method for improving glycaemic control in diabetes
US6011155A (en) * 1996-11-07 2000-01-04 Novartis Ag N-(substituted glycyl)-2-cyanopyrrolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
US20040037818A1 (en) * 1998-07-30 2004-02-26 Brand Stephen J. Treatment for diabetes
CO5150173A1 (es) * 1998-12-10 2002-04-29 Novartis Ag Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
PT1741446E (pt) * 2000-01-21 2008-05-09 Novartis Pharma Ag Combinações incluindo inibidores da dipeptidilpeptidase-iv e agentes anti-diabéticos
HU229042B1 (en) * 2000-03-31 2013-07-29 Prosidion Ltd Method for the improvement of islet signaling in diabetes mellitus and for its prevention
IL156828A0 (en) * 2001-01-12 2004-02-08 Waratah Pharmaceuticals Inc Prolonged efficacy of islet neogenesis therapy methods with a gastrin/cck receptor ligand and an egf receptor ligand composition in subjects with preexisting diabetes
EP1385935A4 (en) * 2001-03-29 2004-09-15 Ixion Biotechnology Inc METHOD FOR TRANSDIFFERENTIATION OF NON-PANCREATIC STEM CELLS IN THE PANCREAS DIFFERENTIATION PATHWAY
US7037504B2 (en) * 2001-10-23 2006-05-02 Waratah Pharmaceuticals, Inc. Epidermal growth factor protein and gene, and methods of use therefor
CA2494134A1 (en) * 2002-05-24 2003-12-04 Waratah Pharmaceuticals, Inc. Treatment for diabetes
US7560425B2 (en) * 2002-06-07 2009-07-14 Waratah Pharmaceuticals Inc. Pharmaceutical composition consisting of rapamycine and gastrin 17(LEU15) and a method for treating diabetes
EP1837031B1 (en) * 2002-06-07 2009-10-14 Waratah Pharmaceuticals, Inc. Compositions and methods for treating diabetes
KR20050074492A (ko) * 2002-10-22 2005-07-18 와라타 파마수티컬즈, 인크. 당뇨병의 치료
US20040229810A1 (en) * 2002-10-22 2004-11-18 Antonio Cruz Gastrin compositions and formulations, and methods of use and preparation
US20090202494A1 (en) * 2004-01-30 2009-08-13 Antonio Cruz Combined use of glp-1 agonists and gastrin for regulating blood glucose levels

Similar Documents

Publication Publication Date Title
JP2013155195A5 (https=)
JP2009538348A5 (https=)
WO2009076173A3 (en) Fluorinated tripeptide hcv serine protease inhibitors
WO2008131149A3 (en) Crystal forms of saxagliptin and processes for preparing same
JP2009510134A5 (https=)
EP2341065A3 (en) Inhibitors of serine proteases, particularly HCV NS3-NS4a protease
NZ592705A (en) 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
WO2008019266A3 (en) Acyclic, pyridazinone-derived hepatitis c serine protease inhibitors
TW200400199A (en) Hepatitis C inhibitor tri-peptides
EP1673385A1 (en) Macrocyclic peptides active against the hepatitis c virus
WO2007143694A3 (en) Macrocyclic oximyl hepatitis c protease inhibitors
WO2009076166A3 (en) Oximyl hcv serine protease inhibitors
WO2008021871A3 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
JP2013503862A5 (https=)
WO2011080102A3 (en) Glp-1 analogues and derivatives
WO2009053828A3 (en) P3 hydroxyamino macrocyclic hepatitis c serine protease inhibitors
JP2010505831A5 (https=)
WO2008021956A3 (en) Acylaminoheteroaryl hepatitis c virus protease inhibitors
JP2010536714A5 (https=)
WO2008069917A3 (en) Novel cyclic peptides
JP2006514104A5 (https=)
JP2006506942A5 (https=)
JP2010513327A5 (https=)
JP2017534675A5 (https=)
MX2010008108A (es) Inhibidores de proteasa de serina de tripéptido de virus de hepatitis c (hcv) que contienen heteroarilo.